FIGURE 4.

Effect of BFA and a proteasome inhibitor on the recognition of the J6R(303–311) or the D1R(808–817) viral epitopes. RMA-HLA-B*0702 target cells infected for 16 h with VACV at a multiplicity of infection of 40 plaque-forming units/cell were treated with BFA or LC. An ICS assay was used to test for recognition by the J6R(303–311)- (open bars) or D1R(808–817)-specific (closed bars) CD8⁺ T cell lines. The data are expressed as percentage of inhibition ± S.D. as determined by ICS in the presence of the indicated inhibitors and are means of three to four independent experiments. Significant p value, **, p < 0.01. Representative ICS assays with J6R(303–311)- and D1R(808–817)-specific CD8⁺ T cell lines were depicted in the middle and bottom panels, respectively. The percentages of IFN-γ-expressing CD8⁺ T cells are indicated in each dot plot.